EMISPHERE TECHN COM USD0.01 (EMIS)

0.62
0.01 2.46
OTC
Prev Close 0.61
Open 0.62
Day Low/High 0.62 / 0.62
52 Wk Low/High 0.46 / 0.91
Volume 190.00
Exchange OTC
Shares Outstanding 60.69B
Market Cap 38.84M
Div & Yield N.A. (N.A)

Latest News

Emisphere Reports Second Quarter 2016 Financial Results

Emisphere Reports Second Quarter 2016 Financial Results

Management to Host Conference Call Today at 8:30 AM ET

Emisphere Announces Second Quarter 2016 Earnings Conference Call

Emisphere Announces Second Quarter 2016 Earnings Conference Call

Conference Call/Webcast to be Held Monday, August 15, 2016, at 8:30 AM ET

Emisphere Reports First Quarter 2016 Financial Results

Emisphere Reports First Quarter 2016 Financial Results

Management to Host Conference Call Today at 8:30 AM ET

Emisphere Announces First Quarter 2016 Earnings Conference Call

Emisphere Announces First Quarter 2016 Earnings Conference Call

Conference Call/Webcast to be Held Monday, May 16, 2016, at 8:30 AM ET

Emisphere Reports Fourth Quarter And Full Year 2015 Financial Results

Emisphere Reports Fourth Quarter And Full Year 2015 Financial Results

The Company to Host Conference Call Today at 8:30 AM ET

Emisphere Announces 2015 Earnings Conference Call

Emisphere Announces 2015 Earnings Conference Call

Conference Call/Webcast to be Held Tuesday, March 29, 2016, at 8:30 AM ET

Emisphere Reports Third Quarter 2015 Financial Results

Emisphere Reports Third Quarter 2015 Financial Results

Management to Host Conference Call Today at 8:30 AM ET

Emisphere Announces Third Quarter 2015 Financial Results Conference Call

Emisphere Announces Third Quarter 2015 Financial Results Conference Call

Conference Call/Webcast to be Held Monday, November 16, 2015, at 8:30 AM ET

Emisphere Signs License Agreement With Novo Nordisk To Develop Oral Formulations Of Four Molecules Targeting Metabolic Indications And Amends GLP-1 Agreement

Emisphere Signs License Agreement With Novo Nordisk To Develop Oral Formulations Of Four Molecules Targeting Metabolic Indications And Amends GLP-1 Agreement

Emisphere to Receive $14 Million Upfront for New License and Amendment, Eligible for More Than $207 Million in Milestone Payments, Plus Royalties on Product Sales

Emisphere Highlights Eligen Licensee Novo Nordisk's Entry Into Phase 3a Development Of Oral Semaglutide, A Once Daily Oral GLP-1

Emisphere Highlights Eligen Licensee Novo Nordisk's Entry Into Phase 3a Development Of Oral Semaglutide, A Once Daily Oral GLP-1

Represents a Significant Validation of the Eligen Technology Platform

Emisphere Reports Second Quarter 2015 Financial Results

Emisphere Reports Second Quarter 2015 Financial Results

Management to Host Conference Call Today at 8:30 AM ET

Emisphere Announces Second Quarter 2015 Financial Results Conference Call

Emisphere Announces Second Quarter 2015 Financial Results Conference Call

Conference Call/Webcast to be Held Wednesday, August 12, 2015, at 8:30 AM ET

Emisphere Reports First Quarter 2015 Financial Results

Emisphere Reports First Quarter 2015 Financial Results

Management to Host Conference Call Today at 8:30 AM ET

Emisphere Announces First Quarter 2015 Financial Results Conference Call

Emisphere Announces First Quarter 2015 Financial Results Conference Call

Conference Call/Webcast to be Held Friday, May 15, 2015, at 8:30 AM ET

Emisphere Announces Fourth Quarter And Full Year 2014 Financial Results Conference Call

Emisphere Announces Fourth Quarter And Full Year 2014 Financial Results Conference Call

Conference Call/Webcast to be Held Tuesday, March 31, 2015, at 8:30 AM ET

Emisphere Launches Eligen B12™, The First Oral Prescription Tablet Proven To Normalize B12 Levels Without The Need For An Injection

Emisphere Launches Eligen B12™, The First Oral Prescription Tablet Proven To Normalize B12 Levels Without The Need For An Injection

- Oral tablet offers prescription strength B12 option for the estimated 48 million Americans with a B12 deficiency

Emisphere Technologies Announces Third Quarter 2014 Earnings Conference Call

Emisphere Technologies Announces Third Quarter 2014 Earnings Conference Call

Conference Call/Webcast to be Held Friday, November 14, 2014 at 8:30 AM ET

Emisphere Announces $20 Million Debt Financing To Launch Oral Eligen(R) B12

Emisphere Announces $20 Million Debt Financing To Launch Oral Eligen(R) B12

Agreement Further Extends Maturity Dates on Existing MHR Promissory Notes

Emisphere Technologies, Inc. Announces Second Quarter 2014 Earnings Conference Call

Emisphere Technologies, Inc. Announces Second Quarter 2014 Earnings Conference Call

Conference Call/Webcast to be Held Thursday, August 14, 2014 at 8:30 AM ET

Emisphere Technologies, Inc. Announces First Quarter 2014 Earnings Conference Call

Emisphere Technologies, Inc. Announces First Quarter 2014 Earnings Conference Call

Conference Call/Webcast to be Held Wednesday, May 14, 2014 at 8:30 AM ET